Italian observational study in patients with metastatic colorectal cancer (mCRC) treated with first-line cetuximab based regimen (ObservEr study).
Francesca Di Fabio(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Carmine Pinto(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Lorenzo Pavesi(University of Trento), Francesco Di Costanzo, Oscar Alabiso, Enzo Maria Ruggeri, Paolo Tralongo(Unknown), Giovanni Di Bernardo(University of Campania "Luigi Vanvitelli"), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Giovanni Paolo Ianniello, Raimondo Ferrara(Ospedale Policlinico San Martino), Daris Ferrari, Giovanni Rosti(Ca' Foncello Hospital), Mario Clerico(Ospedale degli Infermi), Salvatore Tumolo, Libero Ciuffreda(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Silvana Chiara(Ospedale Policlinico San Martino), Gerardo Rosati(Ospedale San Carlo), Carmelo Iacono, Ivan Lolli(Gastroenterology Hospital "Saverio de Bellis")
Cited by 1
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
|Journal of Clinical Oncology|2011|763
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684